Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma ; day:11 ; month:11 ; year:2021
South Asian journal of cancer ; (11.11.2021)
- Beteiligte Personen und Organisationen
-
Cyriac, Sanju
Toms, Ajith
Thomas, Sunitha
- DOI
-
10.1055/s-0041-1731911
- URN
-
urn:nbn:de:101:1-2022031921303177512584
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cyriac, Sanju
- Toms, Ajith
- Thomas, Sunitha
Ähnliche Objekte (12)
![The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]](/assets/placeholder/searchResultMediaUnknown.png)
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report